Bisphosphonate製剤およびRaloxifeneのコンプライアンスならびに有害事象調査(千葉県版DEM)

概要

論文の詳細を見る
To pharmacists, DEM (drug event monitoring) means the monitoring of events in patients taking certain drugs. We recently cooperated with pharmacies belonging to the Chiba Pharmaceutical Association to monitor events for bisphosphonates and raloxifene. These drugs were chosen because some of them have short usage records, as they have not been on the market for very long and have complicated dosing requirements. Pharmacies questioned patients who had been prescribed bisphosphonates such as etidronate disodium, alendronate sodium hydrate and sodium risedronate hydrate, or raloxifene hydrochloride with regard to compliance and post-dosing events. The proportions of patients who forgot to take their medication were significantly greater for alendronate and risedronate, which have complicated dosing regimens, than raloxifene, which has less complicated dosing regimens. As for adverse events, the percentages of patients who had gastrointestinal disorders were 15.8% for etidronate, 7.9% for alendronate, 5.7% for risedronate, and 6.1% for raloxifene. Further, incidence of gastrointestinal disorders was higher in patients taking stomach medications such as antacids, gastric acid-secretion inhibitors and gastric mucosa protectors together with alendronate or risedronate. In the present study, pharmacists' questioning of patients taking bisphosphonates or raloxifene clarified the status of compliance and occurrence rates of adverse events. Based on its results, we feel that more efforts should be made to collect patient information and counsel them on their medication in order to enhance the effectiveness and safety of drug therapy.
日本医療薬学会の論文
2008-05-10

Bisphosphonate製剤およびRaloxifeneのコンプライアンスならびに有害事象調査(千葉県版DEM)

スポンサーリンク

概要

著者

関連論文

スポンサーリンク